Literature DB >> 8136412

Carry-over biases in clinical pharmacology.

T J Cleophas1.   

Abstract

If the effect of a treatment carries on after the treatment is withdrawn then the response to a second treatment may well be due in part to the previous treatment. This so called carry-over effect may bias any clinical trial in which subjects are tested more than once. Cross-over studies can be routinely checked for this bias. In other study designs, however, common sense and alertness for unusual patterns in the data are the only defences against it. The amount of carry-over bias in clinical trials can be somewhat minimized by the following measures. Dose-response studies, dose-titration studies, and open evaluation studies should require a sufficient washout period between the administrations of the drugs. Studies using duplicate standard deviations for the estimation of intra-individual reproducibility of a test should routinely include a statistical test for differences between the duplicate data. Self-controlled studies should not be used otherwise than as an initial orientation for a new treatment. Parallel studies should routinely be stratified for symmetry of previous treatments. Studies with subjective variables are frequently influenced by psychological carry-over effects and should, therefore, be validated together with objective variables whenever possible.

Mesh:

Year:  1993        PMID: 8136412     DOI: 10.1515/cclm.1993.31.12.803

Source DB:  PubMed          Journal:  Eur J Clin Chem Clin Biochem        ISSN: 0939-4974


  3 in total

1.  Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.

Authors:  F S Ram; J Wright; D Brocklebank; J E White
Journal:  BMJ       Date:  2001-10-20

Review 2.  Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.

Authors:  F S F Ram; P Sestini
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 3.  Oral theophylline for chronic obstructive pulmonary disease.

Authors:  F S Ram; P W Jones; A A Castro; J A De Brito; A N Atallah; Y Lacasse; R Mazzini; R Goldstein; S Cendon
Journal:  Cochrane Database Syst Rev       Date:  2002
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.